Villanueva, Vicente
D’Souza, Wendyl http://orcid.org/0000-0002-1750-5131
Goji, Hiroko
Kim, Dong Wook
Liguori, Claudio http://orcid.org/0000-0003-2845-1332
McMurray, Rob
Najm, Imad
Santamarina, Estevo http://orcid.org/0000-0003-1915-0335
Steinhoff, Bernhard J.
Vlasov, Pavel http://orcid.org/0000-0001-8321-5864
Wu, Tony
Trinka, Eugen http://orcid.org/0000-0002-5950-2692
,
Funding for this research was provided by:
Eisai
Article History
Received: 8 June 2021
Revised: 3 August 2021
Accepted: 6 August 2021
First Online: 24 August 2021
Declarations
:
: Vicente Villanueva has received honoraria and/or research funds from Angelini, Arvelle, Bial, Eisai, Esteve, GW Pharma, NewBridge, Novartis, UCB Pharma and Zogenix. Wendyl D’Souza’s salary is part-funded by The University of Melbourne. He has received travel, investigator-initiated, scientific advisory board and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel and speaker honoraria from Eisai Australia & Global; advisory board honoraria from Liva Nova and Tilray; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals and Sanofi-Synthelabo; educational, travel and fellowship grants from GSK Neurology Australia; and honoraria from SciGen Pharmaceuticals. He has an equity interest in the device company EpiMinder and health software company KeyLead Health. Hiroko Goji has no conflicts of interest. Dong Wook Kim has no conflicts of interest. Claudio Liguori has no conflicts of interest. Rob McMurray is an employee of Eisai Europe Ltd. Imad Najm has received honoraria from Eisai. Estevo Santamarina has received honoraria and/or research funds from Bial, Eisai, Esteve, GW Pharma and UCB Pharma. Bernhard J. Steinhoff has received consultation fees and/or honoraria from Arvelle, B. Braun Melsungen, Desitin, Eisai, GW Pharma, Neuraxpharm, Precisis, UCB Pharma, and Zogenix. Pavel Vlasov has received consultation fees and/or honoraria from Alkaloid, Eisai, Novartis, Sanofi, Teva and UCB Pharma. Tony Wu has no conflicts of interest. Eugen Trinka has received consultation fees and/or speakers honoraria from Angelini, Argenx, Arvelle, Bial, Biogen-Idec, Boehringer Ingelheim, Eisai, Epilog, EVER Pharma, Genzyme, GL Pharma, GW Pharmaceuticals, Hikma, LivaNova, Marinus, Medtronic, NewBridge, Novartis, Sanofi, and UCB Pharma.
: All human studies outlined in this article were approved by the appropriate ethics committees and have, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All persons gave their informed consent prior to their inclusion in the studies, according to the protocol.
: Not applicable.